Ivermectine Ratiopharm

Ivermectin, the active ingredient in Ivermectine Ratiopharm, is an antiparasitic belonging to the macrocyclic lactone class and is presented as an oral tablet for oral administration. It is used to treat a range of helminthic and ectoparasitic infections, including strongyloidiasis, onchocerciasis, other intestinal worm infestations, and scabies, in adult and pediatric patients as directed by a healthcare professional.

GNH USA supplies Ivermectine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectine Ratiopharm (ivermectin) is employed against several parasitic diseases affecting the gastrointestinal tract and skin.

- Strongyloidiasis: eradicates the intestinal nematode Strongyloides stercoralis, reducing infection burden. - Onchocerciasis: eliminates microfilariae of Onchocerca volvulus, helping control river blindness. - Other intestinal helminth infections: treats various worm infestations such as hookworm and ascariasis, clearing parasites from the gut. - Scabies: kills the Sarcoptes scabiei mite, relieving skin infestation symptoms.

Oral ivermectin may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurological events: seizures, ataxia, or altered consciousness. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Visual disturbances: blurred vision or optic neuritis.

Before prescribing Ivermectine Ratiopharm, clinicians should consider several safety precautions to minimise risk.

- Assess for co‑existing central nervous system disorders: avoid use in patients with severe neurologic disease. - Evaluate liver function: dose adjustment may be needed in hepatic impairment. - Monitor for drug interactions: review concomitant medications that affect P‑glycoprotein or CYP3A4. - Use caution in pediatric patients: follow weight‑based dosing guidelines provided by the prescriber. - Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Ivermectin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., clarithromycin, verapamil): can increase ivermectin exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Other antiparasitics (e.g., albendazole): combined use may increase neurotoxicity risk. - CNS depressants (e.g., benzodiazepines): may potentiate dizziness or sedation.